Injectable Bacitracin’s Lone Indication Should Be Revoked, US FDA Panel Says

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
An advisory committee said the benefit/risk profile for bacitracin injection's use in pediatric pneumonia is not positive.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers